Navigation Links
BIDMC researchers named among 'the most influential scientific minds'
Date:8/21/2014

BOSTON -- Nine researchers from Beth Israel Deaconess Medical Center (BIDMC ) are among the investigators included in "The World's Most Influential Scientific Minds 2014," a comprehensive list compiled by analysts from Thomson Reuters ScienceWatch, a web resource for science metrics and research performance analysis.

The scientists recognized as among the most influential "are performing and publishing work that their peers recognized as vital to the advancement of their science," according to a Thomson Reuters statement. Researchers were identified based on the number of highly cited papers produced during an 11-year period from 2002 to 2012.

BIDMC investigators named on the "Influential Scientific Minds" list include Donald E. Cutlip, MD, CardioVascular Institute; Michael D. Fox, MD, PhD, Department of Neurology; C. Michael Gibson, MD, PhD, CardioVascular Institute; Sharon K. Inouye, MD, MPH, Division of Gerontology; Bruce E. Landon, MD, MBA, Department of Medicine; Jeffrey J. Popma, MD, CardioVascular Institute; Clifford B. Saper, MD, PhD, Department of Neurology; Michael S. Seaman, PhD, Center for Virology and Vaccine Research; and Larry J. Seidman, PhD, Department of Psychiatry.

Inclusion in the list is based on the number of "highly cited" papers that each of the researchers has published in his or her field. Scientific citations refer to the number of times that researchers have been acknowledged, or "cited" by other scientists as having inspired or guided their own research.

"This type of recognition carries enormous weight," said BIDMC's Chief Academic Officer Vikas P. Sukhatme, MD, PhD. "Such an objective analysis indicates the tremendous value of an investigator's work to his or her own field and, more broadly, to biomedical research and the advancement of medical discoveries. We are proud to have investigators representing a wide range of BIDMC's research included in this analysis. Their inclusion is a reflection of the widespread influence that BIDMC research plays in categories that include clinical medicine as well as microbiology, neuroscience, psychiatry and social sciences."

The BIDMC investigators included in the listing of Highly Cited Researchers include:

Donald E. Cutlip, MD, is Section Chief of Interventional Cardiology in BIDMC's CardioVascular Institute. His work addressing stent thrombosis was one of Thomson Reuters' most highly cited papers, providing a standardized method to design and report results evaluating the clinical trials of coronary stents.

Michael D. Fox, MD, PhD, is the Director of the Laboratory for Brain Network Imaging and Modulation in the Department of Neurology. His research focuses on the development of new and improved treatments for neuropsychiatric diseased based on understanding brain networks and the effects of brain stimulation.

C. Michael Gibson, MD, PhD, is an interventional cardiologist who pioneered our understanding of the open artery hypothesis as well the importance of restoring flow downstream in the capillary bed in the "open microvasculature hypothesis" in cases of heart attack. He has invented measures of coronary blood widely used today (TIMI frame count, TIMI myocardial perfusion grade.)

Sharon K. Inouye, MD, MPH, is a member of the Division of Gerontology at BIDMC and Director of the Aging Brain Center in the Institute for Aging Research at Hebrew SeniorLife. Her clinical investigations focus on the diagnosis, risk factors, prevention and outcomes of delirium in elderly patients and the interface of delirium and dementia.

Bruce E. Landon, MD, MBA, is a member of the Department of Medicine at BIDMC and his research focuses on the organization and financing of health care and its relationship to the costs and outcomes of care.

Jeffrey J. Popma, MD, is Director of Interventional Cardiology Clinical Services at BIDMC. His research focuses on the angiographic evaluation of new technology and transcatheter aortic valve replacement. His group has served as the core laboratory for numerous new technologies including those for carotid and coronary applications.

Clifford B. Saper, MD, PhD, Chairman of Neurology at BIDMC, studies the brain circuitry that controls basic functions, including sleep-wake cycles and circadian rhythms, as well as cardiovascular and respiratory function, identifying the brain's sleep-promoting systems as well as brainstem circuitry controlling autonomic and respiratory activity.

Michael S. Seaman, PhD, is an investigator in the Center for Virology and Vaccine Research where his work focuses on the development of a vaccine against HIV-1/AIDS. He conducts both basic research in the laboratory setting and is testing candidate vaccines in human clinical trials.

Larry J. Seidman, PhD, of BIDMC's Department of Psychiatry and Director of the Commonwealth Research Center, studies cognition, brain function and structure and their treatment in youth at risk for psychotic disorders, especially schizophrenia, focusing on development of early intervention and prevention strategies.


'/>"/>

Contact: Bonnie Prescott
bprescot@bidmc.harvard.edu
617-667-7306
Beth Israel Deaconess Medical Center
Source:Eurekalert

Related biology news :

1. BIDMC cardiovascular institute researchers will lead $4 million NIH grant to study micrornas
2. Study by UC Santa Barbara researchers suggests that bacteria communicate by touch
3. UC Santa Barbara researchers discover genetic link between visual pathways of hydras and humans
4. Researchers attempt to solve problems of antibiotic resistance and bee deaths in one
5. UNH researchers find African farmers need better climate change data to improve farming practices
6. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
7. Researchers uncover molecular pathway through which common yeast becomes fungal pathogen
8. Researchers print live cells with a standard inkjet printer
9. Columbia Engineering and Penn researchers increase speed of single-molecule measurements
10. Researchers reveal how a single gene mutation leads to uncontrolled obesity
11. Researchers discover novel therapy for Crohns disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2016)... YORK , Dec. 16, 2016 The global wearable ... USD 12.14 billion by 2021 from USD 5.31 billion in 2016, ... ... is mainly driven by technological advancements in medical devices, launch of ... rising preference for wireless connectivity among healthcare providers, and increasing focus ...
(Date:12/15/2016)... 2016 ... Research and Markets has announced the addition of the ... The report forecasts the global military biometrics market to grow at ... report has been prepared based on an in-depth market analysis with inputs ... prospects over the coming years. The report also includes a discussion of ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
Breaking Biology News(10 mins):
(Date:1/19/2017)... , Jan. 19, 2017  Market Research Future has a ... Market for Liquid Biopsy is growing rapidly and expected to reach ... Market Highlights ... The Global Liquid Biopsy Market has been assessed as a swiftly ... figures and boom in the coming future. There has been a ...
(Date:1/19/2017)... /PRNewswire -- WuXi AppTec, a leading global pharmaceutical, ... platform, today announced that it has acquired HD ... discovery contract research organization (CRO). After completion of ... of WuXi, and will continue to focus on ... The acquisition will further strengthen WuXi,s R&D capability ...
(Date:1/19/2017)... ... January 19, 2017 , ... Genedata, ... (R&D), today announced the launch of Data Science Services , offering ... evolving field of precision medicine. , Data Science Services allows pharmaceutical ...
(Date:1/19/2017)... GAITHERSBURG, Md. , Jan. 19, 2017 ... Inc., a privately-held immunotherapeutics company targeting infectious diseases, ... for the merger of PharmAthene and Altimmune in ... Venture Fund, HealthCap, Truffle Capital and Redmont Capital. ... diversified immunotherapeutics company with four clinical stage and ...
Breaking Biology Technology: